Literature DB >> 21877938

Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP.

Lijuan Ding1, Changji Yuan, Feng Wei, Guangyi Wang, Jing Zhang, Anita C Bellail, Zhaobin Zhang, Jeffrey J Olson, Chunhai Hao.   

Abstract

Glioblastoma-derived stem cells (GSCs) are responsible for the cancer resistance to therapies. We show here that GSC-enriched neurospheres are resistant to the treatment of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) due to the insufficient expression of the death receptor DR4 and DR5 and the overexpression of cellular Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein (c-FLIP). However, treatment with cisplatin leads to the upregulation of DR5 and downregulation of c-FLIP and restores TRAIL apoptotic pathway in the neurospheres. This study suggests that the combined treatment of TRAIL and cisplatin can induce apoptosis in GSCs and thus provide an effective treatment of glioblastomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21877938      PMCID: PMC3255792          DOI: 10.3109/07357907.2011.605412

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  48 in total

1.  Chemical genetics reveals a complex functional ground state of neural stem cells.

Authors:  Phedias Diamandis; Jan Wildenhain; Ian D Clarke; Adrian G Sacher; Jeremy Graham; David S Bellows; Erick K M Ling; Ryan J Ward; Leanne G Jamieson; Mike Tyers; Peter B Dirks
Journal:  Nat Chem Biol       Date:  2007-04-08       Impact factor: 15.040

2.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.

Authors:  Shideng Bao; Qiulian Wu; Sith Sathornsumetee; Yueling Hao; Zhizhong Li; Anita B Hjelmeland; Qing Shi; Roger E McLendon; Darell D Bigner; Jeremy N Rich
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

3.  CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.

Authors:  T A Röhn; B Wagenknecht; W Roth; U Naumann; E Gulbins; P H Krammer; H Walczak; M Weller
Journal:  Oncogene       Date:  2001-07-12       Impact factor: 9.867

4.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

5.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

Authors:  Jeongwu Lee; Svetlana Kotliarova; Yuri Kotliarov; Aiguo Li; Qin Su; Nicholas M Donin; Sandra Pastorino; Benjamin W Purow; Neil Christopher; Wei Zhang; John K Park; Howard A Fine
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

6.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells.

Authors:  S G M Piccirillo; B A Reynolds; N Zanetti; G Lamorte; E Binda; G Broggi; H Brem; A Olivi; F Dimeco; A L Vescovi
Journal:  Nature       Date:  2006-12-07       Impact factor: 49.962

7.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  Heat shock protein 90alpha recruits FLIPS to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma.

Authors:  Amith Panner; Joseph C Murray; Mitchel S Berger; Russell O Pieper
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

9.  Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.

Authors:  Peng Wang; Jing Zhang; Anita Bellail; Wen Jiang; Judith Hugh; Norman M Kneteman; Chunhai Hao
Journal:  Cell Signal       Date:  2007-06-21       Impact factor: 4.315

10.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.

Authors:  Gentao Liu; Xiangpeng Yuan; Zhaohui Zeng; Patrizia Tunici; Hiushan Ng; Iman R Abdulkadir; Lizhi Lu; Dwain Irvin; Keith L Black; John S Yu
Journal:  Mol Cancer       Date:  2006-12-02       Impact factor: 27.401

View more
  38 in total

1.  Attenuation of lung cancer stem cell tumorigenesis and metastasis by cisplatin.

Authors:  Shenxu Wang; Sai Ma; Xiujuan Li; Zengfu Xue; Xiaotian Zhang; Weiwei Fan; Yongzhan Nie; Kaichun Wu; Xiaoyuan Chen; Feng Cao
Journal:  Exp Lung Res       Date:  2014-08-25       Impact factor: 2.459

2.  TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo.

Authors:  Benny Perlstein; Susan A Finniss; Cathie Miller; Hana Okhrimenko; Gila Kazimirsky; Simona Cazacu; Hae Kyung Lee; Nancy Lemke; Shlomit Brodie; Felix Umansky; Sandra A Rempel; Mark Rosenblum; Tom Mikklesen; Shlomo Margel; Chaya Brodie
Journal:  Neuro Oncol       Date:  2012-11-08       Impact factor: 12.300

3.  Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin.

Authors:  Thomas G Weber; Thomas Pöschinger; Stefanie Galbán; Alnawaz Rehemtulla; Werner Scheuer
Journal:  Neoplasia       Date:  2013-08       Impact factor: 5.715

4.  The XIAP inhibitor Embelin enhances TRAIL-induced apoptosis in human leukemia cells by DR4 and DR5 upregulation.

Authors:  Rong Hu; Ying Yang; Zhuogang Liu; Huinan Jiang; Ke Zhu; Jia Li; Wenhui Xu
Journal:  Tumour Biol       Date:  2014-10-08

5.  Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.

Authors:  Seong Muk Kim; Ji Sun Woo; Chang Hyun Jeong; Chung Heon Ryu; Jae-Deog Jang; Sin-Soo Jeun
Journal:  Stem Cells Transl Med       Date:  2014-01-16       Impact factor: 6.940

Review 6.  Developing TRAIL/TRAIL death receptor-based cancer therapies.

Authors:  Xun Yuan; Ambikai Gajan; Qian Chu; Hua Xiong; Kongming Wu; Gen Sheng Wu
Journal:  Cancer Metastasis Rev       Date:  2018-12       Impact factor: 9.264

7.  Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy.

Authors:  Jian Teng; Seyedali Hejazi; Christian E Badr; Bakhos A Tannous
Journal:  Stem Cells       Date:  2014-08       Impact factor: 6.277

8.  Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.

Authors:  Yan Liu; Oriana E Hawkins; Anna E Vilgelm; Jeffrey S Pawlikowski; Jeffrey A Ecsedy; Jeffrey A Sosman; Mark C Kelley; Ann Richmond
Journal:  Clin Cancer Res       Date:  2015-07-07       Impact factor: 12.531

Review 9.  Harnessing the apoptotic programs in cancer stem-like cells.

Authors:  Ying-Hua Wang; David T Scadden
Journal:  EMBO Rep       Date:  2015-08-07       Impact factor: 8.807

10.  The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma.

Authors:  Bo Zhang; Hong Shan; Dan Li; Zheng-Ran Li; Kang-Shun Zhu; Zai-Bo Jiang
Journal:  Cancer Biol Ther       Date:  2012-08-24       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.